 |
 |
 |
 |
Fibrotic disorders
CTGF stimulates the production of collagen, fibronectin, and laminin,
key components of the extracellular matrix and critical to scar
formation, as part of the normal wound healing response and tissue
repair. However, when these processes go awry, CTGF is overexpressed
and causes excessive production and accumulation of scar material,
leading to chronic fibrosis, a debilitating condition that can
eventually cause failure of the affected organ. FibroGen's research
on novel therapies to treat fibrosis has resulted in the discovery
and development of FG-3019, the Company's first anti-CTGF therapeutic
in clinical development for lung fibrosis. |
|
|
|
